Monocyte Chemoattractant Protein-1 (MCP-1) as a Potential Therapeutic Target and a Noninvasive Biomarker of Liver Fibrosis Associated With Transient Myeloproliferative Disorder in Down Syndrome.

Kobayashi K, Yoshioka T, Miyauchi J et al.

Departments of *Pediatrics ¶Pediatric Surgery #Diagnostic Pathology, Hyogo Prefectural Amagasaki General Medical Center, Hyogo Departments of †Pediatric Hematology and Oncology Research ‡Pathology, National Research Institute for Child Health and Development, Tokyo §Department of Pathology and Laboratory Medicine, Tokyo Dental College Ichikawa General Hospital, Chiba ∥Department of Pathology, Tokai University School of Medicine, Kanagawa, Japan.

Journal of pediatric hematology/oncology. Mar 2017.

Liver fibrosis is one of the common complications of transient myeloproliferative disorder (TMD) in Down syndrome (DS), but the exact molecular pathogenesis is largely unknown. We herein report a neonate of DS with liver fibrosis associated with TMD, in which we performed the serial profibrogenic cytokines analyses. We found the active monocyte chemoattractant protein-1 expression in the affected liver tissue and also found that both serum and urinary monocyte chemoattractant protein-1 concentrations are noninvasive biomarkers of liver fibrosis. We also showed a prospective of the future anticytokine therapy with herbal medicine for the liver fibrosis associated with TMD in DS.


Leave a Reply

Your email address will not be published.